Frankfurt
21.11.24
08:08 Uhr
0,109 Euro
0,000
0,00 %
0,00 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | NEXTCELL PHARMA AB: QVance Announces Partnership | 2 | Cision News | ||
| 08.11. | NEXTCELL PHARMA AB: QVance AB Publishes Article on Particulates in Cell and Gene Therapy Products in Collaboration with ISCT | 2 | Cision News | ||
| 04.11. | NextCell Pharma AB participates in BIO-Europe 2024 and welcomes a visit from Minister Ebba Busch | 1 | Cision News | ||
| 24.10. | NextCell Pharma AB: NextCell publishes its Year-End Report 2023/2024 | 18 | GlobeNewswire (Europe) | NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Year-End Report for the period September 1, 2023 - August 31, 2024. The report is available on the company's website: https://www.nextcellpharma.com/en/investorsfinancial-report.... ► Artikel lesen | |
| 08.10. | NEXTCELL PHARMA AB: NextCell Pharma invited to present in Tokyo | 3 | Cision News | ||
| 04.10. | NEXTCELL PHARMA AB: ProTrans highlighted as a promising treatment for type 1 diabetes in Dagens Medicin | 2 | Cision News | ||
| 25.07. | NEXTCELL PHARMA AB: NextCell publishes its Interim Report 3 2023/2024 | 1 | Cision News | ||
| NEXTCELL PHARMA Aktie jetzt für 0€ handeln | |||||
| 12.07. | Nasdaq Stockholm AB: New equity rights for trading, NextCell Pharma AB TO 2 | 259 | GlobeNewswire | At the request of NextCell Pharma AB, NextCell Pharma AB's equity rights will
be traded on First North Growth Market as from July 15, 2024.
Securit NextCell Pharma AB TO 2 ... ► Artikel lesen | |
| 04.07. | NEXTCELL PHARMA AB: NextCell carries out a directed issue of units to guarantors in connection with the completed rights issue | 1 | Cision News | ||
| 17.06. | NEXTCELL PHARMA AB: NextCell's rights issue oversubscribed | 1 | Cision News | ||
| 12.06. | NEXTCELL PHARMA AB: The paediatric diabetes study gets the green light to treat the age group 7 - 11 years | 1 | Cision News | ||
| 11.06. | NEXTCELL PHARMA AB: The Board of Directors and management sign in addition to subscription commitments | 1 | Cision News | ||
| 10.06. | NEXTCELL PHARMA AB: NextCell publishes supplement to the prospectus regarding the rights issue | 1 | Cision News | ||
| 05.06. | NEXTCELL PHARMA AB: Cellaviva becomes an independent company under NextCell Pharma | 1 | Cision News | ||
| 04.06. | NEXTCELL PHARMA AB: NextCell procures top guarantee in ongoing rights issue | 3 | Cision News | ||
| 31.05. | NEXTCELL PHARMA AB: The subscription period in NextCell's rights issue commences today | 1 | Cision News | ||
| 30.05. | NEXTCELL PHARMA AB: NextCell publishes prospectus in connection with the rights issue of units of approximately SEK 40.1 million | 1 | Cision News | ||
| 28.05. | NEXTCELL PHARMA AB: Single treatment with ProTrans demonstrates long-term therapeutic effect over 5 years | 2 | Cision News | ||
| 27.05. | Bulletin from the Extraordinary General Meeting of NextCell Pharma AB (publ) | 1 | Cision News | ||
| 27.05. | XFRA CAPITAL ADJUSTMENT INFORMATION - 27.05.2024 | 704 | Xetra Newsboard | Das Instrument 37P FR0010341032 FONCIERE INEA SA EO 14,39 EQUITY wird ex Kapitalmassnahme gehandelt am 27.05.2024 The instrument 37P FR0010341032 FONCIERE INEA SA EO 14,39 EQUITY is traded ex capital... ► Artikel lesen |
Seite:
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADMA BIOLOGICS | 21,370 | 0,00 % | Adma Biologics Aktie: Erholung nach starkem Kursrückgang | ||
| RECURSION PHARMACEUTICALS | 6,040 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| EVOTEC | 9,855 | -0,50 % | Märkte am Morgen: Bitcoin, Talanx, Evotec, ASML, Infineon, Domino's Pizza, Palantir | Der DAX sich gestern von seiner starken Seite präsentiert und kräftig zugelegt. Am Ende ging der Leitindex 1,37 Prozent höher bei 19.263 Punkten aus dem Handel. Heute muss er mit unterschiedlichen Vorgabe... ► Artikel lesen | |
| QIAGEN | 40,250 | +3,63 % | Neue 6,00% Aktienanleihe mit Barriere auf QIAGEN in Zeichnung | München (www.anleihencheck.de) - Die Experten vom Zertifikate-Team der Bank Vontobel Europe AG bieten eine neue Aktienanleihe (ISIN DE000VC7RDU1/ WKN VC7RDU) mit Barriere auf die Aktie von QIAGEN (ISIN... ► Artikel lesen | |
| QUANTUM-SI | 1,400 | 0,00 % | Quantum-Si Inc - 8-K, Current Report | ||
| 89BIO | 7,980 | 0,00 % | 89bio, Inc.: 89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting 2024 | SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 59,76 | 0,00 % | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
| RELAY THERAPEUTICS | 4,660 | 0,00 % | Aktie von Relay Therapeutics erreicht 52-Wochen-Tief bei 5,59 US-Dollar | ||
| STRUCTURE THERAPEUTICS | 32,710 | 0,00 % | Structure Therapeutics reports Q3 results | ||
| SPRINGWORKS THERAPEUTICS | 37,440 | 0,00 % | SpringWorks started at outperform by Evercore ahead of FDA decision | ||
| 4D MOLECULAR THERAPEUTICS | 8,410 | 0,00 % | Analyst Expectations For 4D Molecular Therapeutics' Future | ||
| DYNE THERAPEUTICS | 30,000 | 0,00 % | Wissenschaftliche Leiterin von Dyne Therapeutics verkauft Aktien im Wert von 80.539 US-Dollar | ||
| CULLINAN THERAPEUTICS | 12,580 | 0,00 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 | Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune diseases Cullinan will share details of global Phase... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 6,740 | 0,00 % | Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) | ||
| VERVE THERAPEUTICS | 4,550 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen |
NEXTCELL PHARMA AB gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,109 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEXTCELL PHARMA AB finden Sie auf Wallstreet Online.
